Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions — STRAVI  

Vitiligo Clinical Trial

Official title: Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions

Status Recruiting

Clinical Trial Summary

The purpose of this study is to perform an in-depth analysis of the molecular pathways involved in lesions responding to current treatment and lesions not responding to current treatment

Clinical Trial Description

Treatment strategy: combination of oral mini-pulse of methylprednisolone 16mg twice a week + phototherapy Ultraviolet B (UVB) TL01, 2 times a week.

One skin biopsy will be performed at baseline and two skin biopsies at month 3 and month 6 on the same area forearms (excluding skin folds) Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.

Principal Objective:

The aim of this study is to perform an in-depth analysis of vitiligo skin and blood samples taken during the course of a standard therapy to identify pathways involved in the repigmentation.

Secondary Objectives:

• Evolution of Vitiligo Disease in relation of patient profile

• Evolution of the activity of vitiligo in relation of patient profile The statistical and bioinformatics analyzes will be carried out on the data resulting from research with correlation to clinical data. ;

Related Conditions & MeSH terms

• Vitiligo

• NCT number: NCT05927272
• Study type: Interventional
• Source: University Hospital, Bordeaux
• Contact: Julien SENESCHAL, MD, PhD
• Phone: +33 (0)5 56 79 49 63
• Email: julien.seneschal@chu-bordeaux.fr
• Status: Recruiting
• Phase: N/A
• Start date: April 10, 2024
• Completion date: October 9, 2025